<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039182</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02466</org_study_id>
    <secondary_id>SWOG-S0218</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>CDR0000069360</secondary_id>
    <nct_id>NCT00039182</nct_id>
  </id_info>
  <brief_title>Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung</brief_title>
  <official_title>A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) in Patients With Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This&#xD;
      phase II trial is studying how well erlotinib works in treating patients with malignant&#xD;
      mesothelioma of the lung&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the 1-year survival rate in patients with unresectable malignant pleural&#xD;
      mesothelioma treated with erlotinib.&#xD;
&#xD;
      II. Determine the response rate in patients with measurable disease treated with this drug.&#xD;
&#xD;
      III. Determine the frequency and severity of toxic effects of this drug in these patients.&#xD;
&#xD;
      IV. Measure epidermal growth factor receptor (EGFR) expression, EGFR gene amplification, and&#xD;
      other activation products in the EGFR signaling pathway in tumor samples and correlate with&#xD;
      clinical outcomes in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 6 months for 2 years and then annually for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study within 14-18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>1 year</time_frame>
    <description>Erlotinib hydrochloride will not be of further interest if the true one-year survival rate is 35% or less, but of considerable interest if 55% or more.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RECIST response rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Association between EGFR expression with survival and response</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Advanced Malignant Mesothelioma</condition>
  <condition>Epithelial Mesothelioma</condition>
  <condition>Recurrent Malignant Mesothelioma</condition>
  <condition>Sarcomatous Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignant pleural mesothelioma&#xD;
&#xD;
               -  Epithelial&#xD;
&#xD;
               -  Sarcomatous&#xD;
&#xD;
               -  Biphasic&#xD;
&#xD;
          -  Measurable or nonmeasurable disease&#xD;
&#xD;
          -  Not amenable to extrapleural pneumonectomy&#xD;
&#xD;
          -  No known CNS metastases&#xD;
&#xD;
          -  Performance status - Zubrod 0-1&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT or SGPT no greater than 1.5 times ULN (5 times ULN if liver involvement of tumor)&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
          -  No gastrointestinal tract disease resulting in an inability to take oral medication or&#xD;
             a requirement for IV alimentation&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No intractable nausea or vomiting&#xD;
&#xD;
          -  Must be able to swallow and/or receive enteral medications via gastrostomy feeding&#xD;
             tube&#xD;
&#xD;
          -  No known history of the following:&#xD;
&#xD;
               -  Dry eye syndrome&#xD;
&#xD;
               -  Sjogren's syndrome&#xD;
&#xD;
               -  Keratoconjunctivitis sicca&#xD;
&#xD;
               -  Exposure keratopathy&#xD;
&#xD;
               -  Fuch's dystrophy&#xD;
&#xD;
               -  Other active disorders of the cornea&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No HIV-positive patients receiving combination antiretroviral therapy&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except adequately treated basal cell&#xD;
             or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer&#xD;
             that is in complete remission&#xD;
&#xD;
          -  No prior biologic therapy for this tumor&#xD;
&#xD;
          -  No prior chemotherapy for this tumor&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery (e.g., thoracotomy or laparotomy),&#xD;
             excluding minor surgeries (e.g., mediastinoscopy, thoracoscopy, or minor biopsies)&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
          -  No prior investigational anticancer agents for this tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Garland</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Oncology Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

